The hosts speculate on why an HIV vaccine was not prioritized sooner if the technology existed. They suggest that the global market for a respiratory virus vaccine is significantly larger and more profitable than the market for an AIDS vaccine. The discussion touches on the potential for covering up adverse events during mass-scale rollouts.